Intellectia LogoIntellectia
Product
Resources
Markets
News
Partner Program
Pricing
Log inTry for Free
Intellectia Logo
Log in
Intellectia Logo

Product

Features
Financial AI Agent
Stock Technical Analysis
Stock Monitor
Hedge Fund Tracker
AI Screener
Trading Strategies
AI Stock Picker
Swing Trading
Quant AI
Stock Chart Patterns
Daytrading Center
AI Earnings Prediction
Whales Auto Tracker
Backtesting Playground

Resources

Learn
Blog
Earnings
Tutorial
Help Center
Company
About Us
Contact
Press
Reward Program
Partner Program
Tools
Dividend Calculator
Dividend Yield Calculator
Options Profit Calculator
Compare
TradingView
SeekingAlpha

Markets

Trending Stocks
Hot Crypto
Trending News
All Stocks

News

Trading News
Overview
Top News
Daily Market Brief
Earnings
Latest
Newswire
Stock News
Crypto News
Monitor News
Partner ProgramPricing
Start for Free
  1. Home
    2. >
  2. Stock
    3. >
  3. ENTO
stocks logo

ENTO

-
collectAdd to Watchlistadvanced chartAdvanced Chart
$
0.000
0(0.000%)1D
collectadvanced chart
    Overview
    Forecast
    Valuation
    Earnings
High
--
Open
--
VWAP
--
Vol
--
Mkt Cap
--
Low
--
Amount
--
EV/EBITDA(TTM)
--
Total Shares
--
EV
--
EV/OCF(TTM)
--
P/S(TTM)
--
AI Stock Picker
AI Stock Picker

Valuation Metrics

The current forward P/E ratio for Entero Therapeutics Inc (ENTO.O) is 0.00, compared to its 5-year average forward P/E of -3.44. For a more detailed relative valuation and DCF analysis to assess Entero Therapeutics Inc 's fair value, click here.
  • Forward PE
  • Forward EV/EBITDA
  • Forward PS

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PE
-3.44
Current PE
0.00
Overvalued PE
6.10
Undervalued PE
-12.98

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average EV/EBITDA
0.00
Current EV/EBITDA
0.00
Overvalued EV/EBITDA
0.00
Undervalued EV/EBITDA
0.00

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PS
0.08
Current PS
0.00
Overvalued PS
0.44
Undervalued PS
-0.28
Financial AI Agent
Financial AI Agent

Financials

Annual
Quarterly
N/A
Total Revenue
N/A
Operating Profit
N/A
Net Income after Tax
N/A
EPS - Diluted
N/A
Free Cash Flow

Trading Trends

  • Insider
  • Hedge Fund
  • Congress Trading
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Hedge Fund
Hedge Funds are Neutral. There are no significant trading trends over the last quarter.
Sold
Bought
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Intellectia AI SwingMax
Intellectia AI SwingMax

ENTO News & Events

Events Timeline

(ET)
2025-11-28
08:03:39
Entero Therapeutics Rebrands as GridAI
select
2025-11-13 (ET)
2025-11-13
08:39:56
Entero Therapeutics' Grid AI is in the process of forming its U.S. leadership team.
select
2025-11-06 (ET)
2025-11-06
09:23:42
Entero Therapeutics Enters LOI to Merge LV Grid Team with Grid AI
select
Sign Up For More Events
Sign Up For More Events

News

[object Object]
Preview
2.0
12-01NASDAQ.COM
Biotech Stocks Surge in After-Hours Trading with Gains from BioAtla, Entero, and Sonnet

  • BioAtla Inc. Gains: BioAtla's shares surged 13.94% in after-hours trading, attributed to investor reactions to recent financing agreements, despite no new company-specific news.

  • Metagenomi Inc. and PAVmed Inc. Movements: Metagenomi's stock rose 5.71% with no new updates, while PAVmed advanced 5.72% after reporting a significant net loss and a sharp decline in revenue.

  • Precision BioSciences' Positive Outlook: Precision BioSciences gained 2.94% after announcing it will present Phase 1 trial data at an upcoming conference, boosting investor optimism.

  • Entero Therapeutics Rebranding: Entero Therapeutics' shares increased 3.68% following its announcement of a rebranding to GridAI Technologies Corp., effective December 1, 2025, along with a new ticker symbol.

[object Object]
Preview
4.5
11-29NASDAQ.COM
Entero Therapeutics Shares Rise 5% Before Transitioning to GridAI

  • Company Name Change: Entero Therapeutics, Inc. will rebrand as GridAI Technologies Corp. and change its ticker to GRDX, effective December 1, 2025, following its acquisition of GRID AI Corp.

  • Strategic Shift: The rebranding reflects a strategic pivot from Entero's focus on gastrointestinal diseases to AI-driven energy infrastructure, specifically software for managing distributed energy resources.

  • Market Reaction: The announcement led to a 5.28% increase in stock price, with heavier-than-usual trading volume as investors responded to the company's new direction.

  • Stock Performance: Entero's stock has a 52-week range of approximately $1.20 to $4.10, indicating fluctuations in its market value prior to the announcement.

[object Object]
Preview
7.5
11-19TipRanks
NASDAQ: ENTO Secures Hyperscale Agreement in Texas as Its $50M Industrial Software Platform Joins the AI Competition

  • AI Infrastructure Growth: The rapid expansion of AI infrastructure, particularly in Texas, is driven by the increasing demand for electricity to power massive AI data centers, which are now operating like industrial complexes.

  • Grid AI's Strategic Position: Entero Therapeutics' subsidiary, Grid AI, has secured a significant partnership with a major AI developer, positioning itself as a key player in the energy orchestration needed for these large-scale facilities.

  • Revenue Potential: Grid AI is projected to experience substantial revenue growth, with a forecasted 524% increase from 2027 to 2029, driven by multi-campus deployments and long-term contracts.

  • Broader Ecosystem Impact: The AI revolution encompasses not just software but also energy management and infrastructure, highlighting the importance of companies like Grid AI in the overall industrial ecosystem supporting AI advancements.

Sign Up For More News

People Also Watch

FAQ

arrow icon

What is Entero Therapeutics Inc (ENTO) stock price today?

The current price of ENTO is 0 USD — it has increased 5.02 % in the last trading day.

arrow icon

What is Entero Therapeutics Inc (ENTO)'s business?

GridAI Technologies Corp., formerly Entero Therapeutics, Inc., offers a grid-edge, artificial intelligence (AI)-driven software and control platform that enables utilities, retail energy providers, and large power users to dynamically manage load and distributed energy resources, including battery energy storage systems. It applies real-time AI scheduling and optimization to orchestrate devices, fleets, and grid-scale assets. The Company also focuses on the development of targeted, non-systemic therapies for gastrointestinal (GI) diseases. The Company's programs address significant unmet needs in GI health and comprise development of Adrulipase, a recombinant lipase enzyme designed to enable the digestion of fats and other nutrients in cystic fibrosis and chronic pancreatitis patients with exocrine pancreatic insufficiency.

arrow icon

What is the price predicton of ENTO Stock?

Wall Street analysts forecast ENTO stock price to fall over the next 12 months. According to Wall Street analysts, the average 1-year price target for ENTO is  USD with a low forecast of USD and a high forecast of USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

arrow icon

What is Entero Therapeutics Inc (ENTO)'s revenue for the last quarter?

Entero Therapeutics Inc revenue for the last quarter amounts to 0.00 USD, decreased % YoY.

arrow icon

What is Entero Therapeutics Inc (ENTO)'s earnings per share (EPS) for the last quarter?

Entero Therapeutics Inc. EPS for the last quarter amounts to -0.75 USD, decreased -57.39 % YoY.

arrow icon

What changes have occurred in the market's expectations for Entero Therapeutics Inc (ENTO)'s fundamentals?

The market is revising No Change the revenue expectations for Entero Therapeutics, Inc. (ENTO) for FY2025, with the revenue forecasts being adjusted by % over the past three months. During the same period, the stock price has changed by 10.74%.
arrow icon

How many employees does Entero Therapeutics Inc (ENTO). have?

Entero Therapeutics Inc (ENTO) has 2 emplpoyees as of December 05 2025.

arrow icon

What is Entero Therapeutics Inc (ENTO) market cap?

Today ENTO has the market capitalization of 0.00 USD.

Intellectia LogoIntellectiaIntellectia LogoIntellectia

Redefine Your Investment Decisions

TwitterTwitterYoutubeYoutubeQuoraQuoraDiscordDiscordLinkedinLinkedinTelegramTelegram
AppStoreGooglePlay

Copyright © 2025 Intellectia.AI. All Rights Reserved.

pci certified logo
Company
HomeContactAbout UsNews Release
Compare
TradingViewSeeking Alpha
Features
Financial AI AgentStock Technical AnalysisStock MonitorHedge Fund TrackerAI ScreenerDaytrading Center
Strategies
AI Stock PickerSwing TradingStock Chart PatternsEarnings TradingDaytrading CenterAI Earnings PredictionQuant AIWhales Auto TrackerBacktesting Playground
Free Tools
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Resource
BlogTutorialEarningsTrending StocksCrypto MarketPartner ProgramTerms of UsePrivacy PolicySecuritySitemap
Start for Free